Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROZAC vs LEXAPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder with or without agoraphobia,Premenstrual dysphoric disorder,Bipolar depression (in combination with olanzapine)
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
Fluoxetine: 4-6 days; norfluoxetine: 4-16 days; extensive accumulation with chronic dosing, steady-state in 4-5 weeks
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Hepatic via CYP2D6, CYP2C9, CYP2C19, and CYP3A4; active metabolite norfluoxetine.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Renal: ~80% (primarily as metabolites, <10% unchanged); fecal: ~15%
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
~94.5% bound to albumin and alpha-1-acid glycoprotein
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
12-42 L/kg; extensive tissue binding, particularly in lungs and brain
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
Oral: 60-80% due to first-pass metabolism; not administered parenterally
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
GFR 10-50 m L/min: administer 50% of usual dose; GFR <10 m L/min: administer 50% of usual dose or use alternative; not removed by hemodialysis.
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
Child-Pugh Class A: no dose adjustment needed; Child-Pugh Class B: reduce dose by 50% or use alternative; Child-Pugh Class C: contraindicated or use alternative with caution.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Children 7-17 years: 10-20 mg orally once daily, initially; may increase to 20-40 mg once daily after ≥1 week; maximum 40 mg once daily.
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
Consider starting dose of 10 mg orally once daily; may increase slowly to 20 mg once daily; maximum 40 mg once daily; monitor for hyponatremia and QT prolongation.
Initial 5 mg orally once daily; maximum 10 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in pediatric patients,Activation of mania/hypomania,QT interval prolongation,Serotonin syndrome,Discontinuation syndrome,Bleeding risk (with NSAIDs/aspirin)
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Hypersensitivity to fluoxetine,Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide or thioridazine
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
Avoid grapefruit juice as it inhibits CYP3A4 and may increase fluoxetine levels. Alcohol may potentiate CNS depression; advise minimal or no alcohol use. No other significant food interactions.
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
First trimester: Studies suggest a small increased risk of cardiovascular malformations, particularly ventricular septal defects, with relative risk approximately 1.5-1.7. Third trimester: Exposure is associated with risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (including irritability, respiratory distress, feeding difficulty). Second trimester: No specific major risks identified beyond general population baseline.
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk. Milk-to-plasma ratio for fluoxetine is approximately 0.29. Infant serum levels can reach up to 10% of maternal therapeutic levels, with norfluoxetine accumulating. Adverse effects reported include irritability, poor feeding, and colic. American Academy of Pediatrics considers fluoxetine as a drug with 'potentially significant' effects; caution is advised, and breastfeeding should be weighed against maternal need.
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Pregnancy can decrease fluoxetine levels due to increased volume of distribution and hepatic metabolism; dose may need to be increased (20-40% on average) in third trimester, with tapering postpartum to pre-pregnancy dose to avoid toxicity. Therapeutic drug monitoring is recommended to maintain efficacy. No specific dose adjustment is standardized; individualization based on clinical response and serum levels is required.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
Commonly used in bulimia nervosa (60 mg/day) and premenstrual dysphoric disorder (20 mg/day continuously or 20 mg/day only during luteal phase). Requires 4-6 weeks for full therapeutic effect. Abrupt discontinuation may cause withdrawal symptoms; taper over 2-4 weeks. Risk of serotonin syndrome when combined with MAOIs, other serotonergic drugs, or linezolid. Lower starting dose (10 mg) in hepatic impairment or elderly. Suicidality warning especially in children, adolescents, and young adults.
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
Take exactly as prescribed, usually once daily in the morning to minimize insomnia.,It may take 4-6 weeks to feel full benefit; do not stop abruptly.,Do not take with MAOIs or within 14 days of stopping MAOIs.,Report any suicidal thoughts, especially during the first few weeks.,Avoid alcohol and grapefruit juice as they may increase side effects.,If you miss a dose, skip it; do not double the next dose.
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROZAC vs LEXAPRO, answered by our medical review team.
PROZAC is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.. LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROZAC and LEXAPRO depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROZAC is: 20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.. The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROZAC and LEXAPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROZAC is classified as Category C. First trimester: Studies suggest a small increased risk of cardiovascular malformations, particularly ventricular septal defects, with relative risk approximately 1.5-1.7. Third tr. LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.